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Abstract
Background: Intraoperative radiofrequency ablation (IRFA) is added to surgery to obtain hepatic clear-
ance of liver metastases. Complications occurring in IRFA should differ from those associated with wedge
or anatomic liver resection.
Methods: Patients with liver metastases treated with IRFA from 2000 to 2010 were retrospectively
analysed. Postoperative outcomes are reported according to the Clavien–Dindo system of classification.
Results: A total of 151 patients underwent 173 procedures for 430 metastases. Of these, 97 procedures
involved IRFA plus liver resection and 76 involved IRFA only. The median number of lesions treated by
IRFA was two (range: 1–11). A total of 123 (71.1%) procedures were carried out in patients who had
received preoperative chemotherapy. The mortality rate was 1.2%. Thirty (39.5%) IRFA-only patients and
45 (46.4%) IRFA-plus-resection patients presented complications. Immediate complications (n = 4) were
associated with IRFA plus resection. American Society of Anesthesiologists (ASA) class, previous
abdominal surgery or hepatic resection, body mass index, number of IRFA procedures, portal pedicle
clamping, total vascular exclusion and preoperative chemotherapy were not associated with a greater
number of complications of Grade III or higher severity. Length of surgery >4 h [odds ratio (OR) 2.67, 95%
confidence interval (CI) 1.1–6.3; P < 0.05] and an associated contaminating procedure (OR 3.72, 95% CI
1.53–9.06; P < 0.005) led to a greater frequency of complications of Grade III or higher.
Conclusions: Mortality and morbidity after IRFA, with or without resection, are low. Nevertheless, long
interventions and concurrent bowel operations increase the risk for septic complications.
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Introduction
Intraoperative radiofrequency ablation (IRFA) to treat patients
with unresectable liver metastases has now been in use for more
than 10 years.1,2 As it is a relatively new surgical technique, assess-
ments of both its technical added value and associations with
potential morbidity and mortality are crucial. Prospective studies
examining patients with unresectable colorectal liver metastases
(CLM) have concluded that longterm survival can be achieved
using radiofrequency ablation (RFA) in an intraoperative
setting.3,4 In patients with complex CLM initially judged to be
unresectable, rates of overall survival of 57.6% at 30 months4 and
43.0% at 5 years3 have been reported. Per-lesion rates of local
recurrence of ablated metastases were 6.5%4 and 4.0%,3 which are
comparable with those reported after hepatectomy in patients
with borderline surgical resectability.5,6 These studies provide
further evidence for the safety and effectiveness of the clinical use
of IRFA as a complementary technique to resection, and it is
already employed with encouraging outcomes in specialized
centres across the world.7–10 The negative prognostic impact of
postoperative complications on survival after hepatic resection of
CLM has been well documented.11–13 Thus, it is important that
postoperative complications associated with surgery for liver
metastases are minimized if potential survival is to be optimized.
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The aim of the present study was to evaluate retrospectively the
morbidity and mortality rates of IRFA, either performed alone or
in combination with resection, at a single centre over a 10-year
period.
Materials and methods
All patients surgically treated for liver metastases with IRFA
without laparoscopy between 2000 and 2010 were retrospectively
identified from data collected prospectively (Medlog 2000®;
Medlog, Inc., San Antonio, TX, USA) in the Digestive Tumour
Unit, Institut Bergonié, Bordeaux, France. Subsequent pro-
cedures were considered as separate and independent in all per-
procedure analyses. This study was approved by the study
centre’s institutional review board and carried out in compliance
with the Helsinki Declaration. No exclusions were made on the
basis of the aetiology of the liver metastasis. For each patient,
surgical decisions were made by a multidisciplinary team
that included oncologists, radiotherapists, radiologists and sur-
geons. All operations were performed by the same surgeon.
Intraoperative assessment always included a complete explora-
tion of the peritoneal cavity, liver mobilization and liver
intraoperative ultrasound (IOUS) examination. The choice of
IRFA or IRFA combined with resection was made during the
surgery after IOUS imaging of the liver based on three aspects:
unresectability of lesions; size of lesions, and sparing of the func-
tional parenchyma (IRFA was the preferred method when pos-
sible). Deep, single-nodule lesions, of <35 mm in diameter and
far from a main biliary duct but possibly close to a hepatic vein
were candidates for ablation, whereas superficial, multi-nodule
lesions of >35 mm or located close to a main biliary duct were
treated with resection.
Intraoperative radiofrequency ablation procedures were per-
formed using straight needles (Integra ME GmbH, Tuttlingen,
Germany) perfused with isotonic saline serum and connected to a
generator (Elektrotom 106 HFTT; Berchtold GmbH & Co. KG,
Tuttlingen, Germany). The needle diameter was 1.2 mm and the
active tips were 10 mm, 15 mm or 20 mm long. The needle was
introduced and treatment performed using ultrasound guidance.
The total energy (joules) delivered per impact was calculated by
the generator’s computer. The duration and number of impacts
depended on the size of each lesion. Vascular occlusions were
sometimes required: a Pringle manoeuvre was performed if the
lesion was located close to a portal vessel, but not in the proximity
of a main portal branch, where IRFA is contraindicated. A hepatic
vein close to the lesion could be clamped. Up to all three hepatic
veins could be clamped and portal blood flow interrupted; this
prevented the cooling of the target and thus achieved greater heat
delivery during the treatment.14
The terminology for hepatectomy is as described by
Couinaud.15 Parenchymal division was performed using the Kelly
clamp-crushing method and completed by a bipolar vessel-sealing
clamp (Ligasure®; Covidien, Inc., Mansfield, MA, USA) for vascu-
lar and biliary structure control. Hepatectomies were usually con-
ducted under intermittent pedicular clamping.16
Complications were exhaustively recorded using the classifica-
tion described by Dindo et al.17 and categorized according to the
time of symptom onset after surgery as immediate (<24 h), early
(1–30 days) or delayed (>30 days). Hepatic failure was defined
according to the definition of the International Study Group
of Liver Surgery18 using biological and clinical signs of hepatocel-
lular dysfunction (ascites, encephalopathy, jaundice). Severe
hepatic failure was defined by the conjunction of prothrombin
time of <50% and serum bilirubin of >50 μmol/l on postoperative
day 5. Hepatobiliary complications included liver abscesses or
collection, biliary stenosis, biliary fistula and biloma. Main
parietal complications encompassed wound abscesses, whereas
intra-abdominal extrahepatic complications were abscesses,
anastomotic leakage and occlusion.
Statistical considerations
Correlations between the occurrence of complications of Grade
III or higher and pre- and intraoperative variables were estab-
lished using univariate analysis (chi-squared and Fisher’s tests for
qualitative data and the Wilcoxon non-parametric test for quan-
titative data).
All variables that were found in univariate analysis to have a
statistically significant association at the P < 0.05 level were
included in the multivariate model using logistic regression with a
stepwise descendant procedure. The odds ratio (OR) with a 95%
confidence interval (95% CI) was chosen as the measure of asso-
ciation. All results are described per procedure. Statistical analyses
were performed using pasw Statistics Version 18.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
A total of 339 patients were treated for liver metastases and reg-
istered in a prospective database between 2000 and 2010. The
present retrospective study includes 151 (44.5%) patients treated
with IRFA. Of these patients, 22 (14.6%) were treated twice and
thus a total of 173 procedures for 430 liver metastases were per-
formed. All data are presented per procedure. Patient characteris-
tics are presented in Table 1 and intraoperative variables are
shown in Table 2. A total of 22 (12.7%) procedures involved the
total vascular exclusion of the liver. Table 3 shows the
perioperative outcomes and complications. Overall morbidity and
mortality rates were 43.4% (95% CI 36.0–50.7; n = 75/173) and
1.2% (n = 2), respectively. Complications of Grade III or higher
occurred in 36 procedures (20.8%, 95% CI 14.8–26.9). Overall, 57
(76.0%) complications occurred between 24 h and 30 days after
surgery. Two deaths were registered in, respectively, an elderly
woman with severe obesity who died of septicaemia and a young
male with anastomotic leakage after concomitant gastric surgery.
Hepatic collections included two hepatic abscesses on the IRFA
site, treated by percutaneous drainage and antibiotics. Two
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subcapsular hematoma were recorded, one of which occurred
after IRFA treatment. Ten bilomas were noted, three of which
occurred after IRFA. Only symptomatic bilomas were treated by
percutaneous drainage. Four biliary stenoses were observed but
only one was symptomatic and required a radiological procedure
for stenting (Grade IIIa). These four patients had all received IRFA
in liver segment IV.
Three intrahepatic vascular thromboses were observed; one
patient (Grade IVa) required intensive care unit (ICU) treatment
because of associated liver failure and hepatic abscesses. Three
biliary fistulae developed in patients treated with IRFA plus resec-
tion. These were treated with percutaneous drainage and achieved
spontaneous closure; one patient required subsequent interven-
tion for drainage.
Six of the patients treated with IRFA combined with resection
presented hepatic failure. One of these patients developed
sinusoidal obstruction syndrome as a result of 12 cycles of preop-
erative chemotherapy with FOLFOX [folinic acid (leucovorin
calcium), fluorouracil (5-FU), oxaliplatin] and required ICU
treatment. Eighteen patients (nine treated with IRFA only and
nine treated with IRFA combined with resection) underwent ext-
rahepatic associated procedures and developed intra-abdominal
extrahepatic complications including intraperitoneal abscesses,
anastomotic leakage and occlusion. Patients treated with IRFA
plus resection were more likely to be prone to blood loss, includ-
ing acute postoperative bleeding and postoperative anaemia
(11.3% of hepatectomies compared with 6.6% of lesions in IRFA-
only patients), although the difference was not significant. Three
Table 1 Characteristics of patients and tumours treated with intraoperative radiofrequency ablation (IRFA) alone or with IRFA plus hepatic
resection across procedures for liver metastases. Data are shown per procedure
IRFA alone IRFA plus resection Total
Procedures, n (%) 76 (43.9%) 97 (56.1%) 173 (100%)
Age at surgery, years, median (range) 63.0 (27–98) 63.0 (21–82) 63.0 (21–98)
ASA score, n (%)
1 17 (22.4%) 34 (35.4%) 51 (29.7%)
2 50 (65.8%) 52 (54.2%) 102 (59.3%)
3 9 (11.8%) 10 (10.4%) 19 (11.0%)
Sex, male, n (%) 44 (57.9%) 61 (62.9%) 105 (60.7%)
Body mass index, median (range) 25.2 (16.5–39.1) 25.4 (18.3–34.3) 25.3 (16.5–39.0)
Prior abdominal surgery, n (%) 58 (76.3%) 80 (82.5%) 138 (79.8%)
Prior hepatectomy, n (%) 19 (25.0%) 26 (26.8%) 45 (26.0%)
Preoperative chemotherapya, n (%) 48 (63.2%) 75 (77.3%) 123 (71.1%)
Liver primary 2 (2.6%) 1 (1.0%) 3 (1.7%)
Liver secondaries 74 (97.3%) 96 (99.0%) 170 (98.3%)
Isolated liver metastases 54 (71.1%) 77 (79.4%) 131 (75.7%)
Synchronous metastases 39 (51.3%) 58 (59.8%) 97 (56.1%)
aMedian of nine cycles.
ASA, American Society of Anesthesiologists.
Table 2 Description of intraoperative variables in patients treated with intraoperative radiofrequency ablation (IRFA) alone or with IRFA plus
hepatic resection. Data are shown per procedure
IRFA only IRFA plus resection Total
Procedures, n (%) 76 (43.9%) 97 (56.1%) 173 (100%)
Length of surgery, h, median (range) 3.5 (1.2–8.5) 3.5 (1.3–7.5) 3.5 (1.2–8.5)
Lesions treated by IRFA, n, median (range) 2 (1–11) 2 (1–8) 2 (1–11)
Associated major hepatectomy, n (%) 0 35 (36.1%) 35 (20.2%)
Associated potentially contaminating procedure, n (%) 24 (31.6%) 14 (14.4%) 38 (22.0%)
Associated treatment of postoperative hernia repair, n (%) 11 (14.5%) 14 (14.4%) 25 (14.5%)
IRFA near biliary tract or vascular structure, n (%) 8 (10.5%) 4 (4.1%) 12 (6.9%)
Vascular clamping, n (%) 35 (46.1%) 39 (40.2%) 74 (42.8%)
Biliary cooling, n (%) 2 (2.6%) 1 (1.0%) 3 (1.7%)
Preventive cholecystectomy, n (%) 13 (17.1%) 18 (18.6%) 31 (17.9%)
Intraoperative transfusion, n (%) 5 (6.7%) 11 (11.3%) 16 (9.3%)
1004 HPB
HPB 2014, 16, 1002–1008 © 2014 International Hepato-Pancreato-Biliary Association
patients treated with IRFA plus resection underwent emergency
surgery for bleeding after hepatic resection. No bleeding was
observed at any of the ablated sites.
Eight parietal complications were recorded in patients who had
received previous abdominal surgery; these included four wound
abscesses, one evisceration requiring surgery, one case of bleeding,
one case of skin necrosis after incisional hernia repair, and one
case of asymptomatic seroma. Three of the patients required
incisional hernia repair during surgery.
Analyses of variables associated with complications of Grade III
or higher are shown in Table 4.
Discussion
The parenchymal trauma of coagulative necrosis caused by IRFA
differs from that induced by a hepatotomy. It is thus reasonable to
expect different patterns of complications from the two
approaches. The study of complications specific to IRFA is chal-
lenging as it is a technique often associated with resection.
Although there are several publications on RFA-induced compli-
cations, many of these are mixed reports that do not distinguish
between the strategies employed (open surgical, laparoscopic and
percutaneous) or report on single approaches and are inconsistent
in the complication factors identified, thus rendering analyses
unreliable and controversial.19–21 The complications reported in
the context of IRFA performed as a stand-alone procedure are
based on small sample sizes, include only early (<30 days after
surgery) complications, and rarely refer to sensitive complication
grading systems.22 Most research groups describe complication
rates of 0–16% and mortality rates of 0–1.8%.22 The overall rate of
complications after IRFA within the current study, as classified
according to the Clavien–Dindo system, was 39.5%. The incidence
of complications of Grade III or higher was 18.4%. In the pro-
spective ARF2003 trial, which used the Clavien–Dindo system, the
complication rates observed were similar at 44.8% for all compli-
cations and 12.2% for complications of Grade III or higher.3
When IRFA is combined with resection, reported complication
rates rise to 12.1–31.0%, and mortality rises to 0–5.2%.23 These
rates should be compared with morbidity and mortality rates after
hepatectomy alone, which are estimated at 20–50% and 0–5%,
respectively.23
The multivariate model revealed that surgery of >4 h in dura-
tion and the association of a potential contaminating procedure
(e.g. an opening of the digestive tract such as in colectomy) were
associated with greater risk for complications of Grade III or
higher. Factors traditionally associated with surgical complica-
tions, such as American Society of Anesthesiologists (ASA)
score,24 previous surgery, body mass index and preoperative
chemotherapy, were not associated with complications after
IRFA. This suggests that IRFA has an additive rather than a spe-
cific effect on associated complications and using it in combina-
tion with a surgical intervention increases the risk for potential
complications.
Indeed, IRFA also has an impact on liver function, albeit small.
This factor should be noted by any surgeon dealing with complex
bilateral diseases for which the consequences of exceeding the
limits of liver function restoration may be critical. Theoretically,
IRFA could induce liver failure in the treatment of large confluent
lesions. Although IRFA is considered to be a parenchyma-sparing
technique, it should be remembered that it is currently regarded as
a complementary treatment to resection and not as a substitute.
Some authors have advanced a step further and have reported
multidisciplinary treatments involving an iterative use of IRFA in
combination with hepatectomy and chemotherapy in the treat-
ment of multiple metastases with good results.7,25
Because of the tissular coagulation necrosis induced by IRFA,
specific complications may differ from those induced by hepa-
tectomy, especially with reference to haemorrhagic complica-
tions, which are a major drawback of liver resection and are
rarely induced by IRFA. This is reflected in the results of the
current study, in which haemorrhagic complications were
reported twice as often in patients submitted to IRFA and
hepatic resection at the same time. However, the fact that biliary
ducts are very sensitive to heat represents the main limitation to
using IRFA in the liver.26 In the current series, biliary stenosis
occurred in four patients with lesions in segment IV. It is now
commonly accepted that lesions situated close to the main
biliary duct are contraindicated for ablation.20 The use of new
ablative techniques, such as electroporation, in high-risk areas
merits further investigation, although recent results have been
disappointing.27
Table 3 Complications in patients treated with intraoperative
radiofrequency ablation (IRFA) alone or with IRFA plus hepatic resec-





n (%) n (%)
Procedures with complications 30 (39.5%) 45 (46.4%)
Complications of Grade II
or lower
16 (21.1%) 23 (23.7%)
Complications of Grade III or
higher
14 (18.4%) 22 (21.7%)
Immediate (<24 h) 0 4 (4.1%)
Early (1–30 days) 24 (31.6%) 33 (34.0%)
Delayed (>30 days) 8 (10.5%) 6 (6.2%)
Hepatobiliary complications 8 (10.5%) 18 (18.6%)
Intra-abdominal extrahepatic
complications
9 (11.8%) 9 (9.3%)
Other complications
Parietal 3 (3.9%) 5 (5.2%)
Pulmonary 6 (7.9%) 5 (5.2%)
Cardiac 2 (2.6%) 5 (5.2%)
Urinary 6 (7.9%) 4 (4.1%)
Neuro-psychiatric 2 (2.6%) 4 (4.1%)
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Table 4 Univariate and multivariate analyses of predictive factors associated with morbidity in patients treated with intraoperative
radiofrequency ablation (IRFA) only (n = 76) or IRFA plus resection (n = 97) across 173 IRFA procedures for liver metastases according to the
Clavien–Dindo grading system






Grade II or lower Grade III or higher P-value P-value OR (95% CI)
Procedure, n (%)
IRFA only 62 (81.6%) 14 (18.4%) 0.49
IRFA plus resection 75 (77.3%) 22 (22.7%)
Age, years
Mean ± SD 62.1 ± 13 57.7 ± 12.2 0.049b 0.047 0.97 (0.94–1.0)
Median (range) 64.0 (21–98) 58.5 (31–78)
Sex, n (%)
Female 60 (88.2%) 8 (11.8%) 0.018 0.10 not retained
Male 77 (73.3%) 28 (26.7%)
ASA score, n (%)
1 42 (82.4%) 9 (17.6%) 0.49
2, 3 94 (77.7%) 27 (22.3%)
Body mass index, n (%)
≤25 kg/m2 68 (81.0%) 16 (19.0%) 0.58
>25 kg/m2 69 (77.5%) 20 (22.5%)
Previous abdominal surgery, n (%)
No 25 (71.4%) 10 (28.6%) 0.21
Yes 112 (81.2%) 26 (18.8%)
Preoperative chemotherapy, n (%)
No 42 (84.0%) 8 (16.0%)
Yes 95 (77.2%) 28 (22.8%) 0.32
Extrahepatic surgery, n (%)
No 100 (87.7%) 14 (12.3%)
Yes 37 (62.7%) 22 (37.3%) <0.001 0.32 not retained
IRFA impacts, n (%)
1 49 (76.6%) 15 (23.4%) 0.14
2 34 (72.3%) 13 (27.7%)
≥3 54 (87.1%) 8 (12.9%)
Pedicle clamping, n (%)
No 79 (79.8%) 20 (20.2%) 0.82
Yes 58 (78.4%) 16 (21.6%)
Contaminating procedure, n (%)
No 116 (85.9%) 19 (14.1%) <0.001 0.004 3.72 (1.53–9.06)
Yes 21 (55.3%) 17 (44.7%)
Operative time, n (%)
≤4 h 100 (85.9%) 15 (14.1%) <0.001 0.025 (1.12–6.30)
>4 h 32 (55.3%) 20 (44.7%)
aChi-squared test.
bWilcoxon test.
OR, odds ratio; 95% CI, 95% confidence interval; SD, standard deviation; ASA, American Society of Anesthesiologists.
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The most specific and practical concern with radiofrequency
(RF)-induced necrosis is its ability to become secondarily infected.
Complications such as liver abscesses resulting from proximity to a
potential source of infection, such as an enterobiliary anastomosis,
were reported 10 years ago by de Baère et al.26 In the present study,
it was observed that areas with necrosis induced by RFA have a
propensity to become infected by occult bacteraemia. The opening
of the digestive tract during a colectomy was enough to induce
homing of bacteria in the RF lesion, an occurrence confirmed as an
independent predictive factor of complications in the multivariate
analysis. For example, the first stage of a two-stage liver procedure
often includes a colectomy to treat the primary lesion and some
IRFA of metastases in the left lobe before a right hepatectomy. An
important issue to be addressed concerns whether changing the
standard antibiotic prophylaxis to a therapeutic course is beneficial
for the patient.
Overall, this study shows that IRFA is a safe technique and
induces a low rate of specific complications. Nevertheless, the use
of IRFA as an additive therapeutic tool is not without cost and
thus it should not be considered as a simple, risk-free procedure
that can be added to a complex procedure without consequence.
The results of this series show that when IRFA is performed in
association with long and complex procedures, it increases the
rate of complications and especially the risk for liver necrotic
abscesses in the context of a digestive tract procedure.
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